ClinicalTrials.Veeva

Menu
C

CHU de Liege | CHR Citadel - Department of Gyneacology and Obstetrics

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Risankizumab
Upadacitinib
Nivolumab
Golimumab
Guselkumab
Adalimumab
Doxorubicin
Enzalutamide
Gemcitabine
Trastuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 41 total trials

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose...

Enrolling
Relapsed or Refractory Multiple Myeloma
Previously Treated Amyloid Light-chain (AL) Amyloidosis
Drug: JNJ-79635322
Locations recently updated

This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through t...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: sigvotatug vedotin
Drug: docetaxel

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not...

Enrolling
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specifi...

Active, not recruiting
HER2-positive Breast Cancer
Drug: T-DM1
Drug: tucatinib

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

Active, not recruiting
Crohn's Disease (CD)
Drug: ABT-494

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The...

Active, not recruiting
Uterine Cervical Neoplasms
Uterine Neoplasms
Drug: fulvestrant
Drug: trastuzumab

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankiz...

Active, not recruiting
Crohn's Disease (CD)
Drug: Risankizumab
Drug: Ustekinumab

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting
Prostate Cancer
Drug: Placebo plus enzalutamide
Drug: talazoparib plus enzalutamide

Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21.Ph...

Active, not recruiting
Follicular Lymphoma
DLBCL
Drug: Cyclophosphamide
Drug: Vincristine

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for teliso...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cer...

Active, not recruiting
Cervical Cancer
Drug: tisotumab vedotin
Drug: topotecan

Trial sponsors

AbbVie logo
T
Seagen logo
Bristol-Myers Squibb (BMS) logo
Janssen (J&J Innovative Medicine) logo
Takeda logo
H
Ipsen logo
Janssen (J&J Innovative Medicine) logo
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems